Key Takeaways:
The Ensign Group Inc. shares fell 6.9% on June 8 after short seller Hunterbrook published a five-month investigation alleging the nursing home operator's profits depend on understaffing facilities and gaming quality metrics while routing taxpayer dollars to executives and affiliates.
"The company's business model relies on inadequate patient care and gaming quality metrics," Hunterbrook said in its report, which also alleged that patients have suffered and died as a result of Ensign's practices. The report triggered investigations by Rosen Law Firm and Levi & Korsinsky, both of which announced probes into potential securities claims on behalf of Ensign shareholders.
Ensign's stock dropped sharply in intraday trading on June 8, erasing roughly $400 million in market value based on the company's $5.8 billion market capitalization before the decline. The selloff came less than six weeks after Ensign Chief Executive Officer Barry Smith told investors on a May 1 earnings call that the company had achieved "record high" occupancy and improving staffing levels.
The allegations center on Ensign's skilled nursing business, which operates more than 300 facilities across the US and derives a significant portion of its revenue from government programs such as Medicare and Medicaid. Hunterbrook's report claimed the company systematically understaffs its facilities to boost margins while submitting inflated billing claims to government payers.
Rosen Law Firm, which has recovered hundreds of millions of dollars for investors in securities class actions, said it is preparing a class action seeking recovery of investor losses. Levi & Korsinsky separately encouraged shareholders who lost money to discuss their legal rights. Both firms noted that investors may be entitled to compensation without out-of-pocket costs through contingency fee arrangements.
The investigations add regulatory and legal risk to a stock that had already seen significant insider selling. Ensign insiders sold 31 times in the past six months with zero purchases, including CFO Suzanne Snapper, who sold 12,831 shares valued at an estimated $2.5 million. Analysts at RBC Capital and Truist Securities maintained price targets of $222 and $215 respectively, implying potential upside from current levels if the company can address the allegations.
The outcome of the investigations will determine whether Ensign faces securities fraud claims or regulatory penalties. Investors will watch for any response from the company and for potential federal agency inquiries into the billing and staffing practices outlined in the Hunterbrook report.
This article is for informational purposes only and does not constitute investment advice.
